Pharmacological Treatment

  • Joachim Weis
  • Markus Horneber
Chapter
First Online:

Abstract

Pharmacological treatment of cancer-related fatigue is primarily based on addressing symptoms and reducing intensifying factors, as well as impacting possible pathophysiological factors. Medications with a very wide range of mechanisms of action are used in treatment.

Keywords

National Comprehensive Cancer Network National Comprehensive Cancer Network Panax Ginseng Moderate Fatigue American Ginseng 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Bruera E, Yennurajalingam S. Challenge of managing cancer-related fatigue. J Clin Oncol. 2010;28:3671–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Howell D, Keller-Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol. 2013;20:e233–46.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Bower JE. Treating cancer-related fatigue: the search for interventions that target those most in need. J Clin Oncol. 2012;30:4449–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Horneber M, Fischer I, Dimeo F, Ruffer JU, Weis J. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int. 2012;109:161–71.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Kuhnt S, Ehrensperger C, Singer S, et al. Prädiktoren tumorassoziierter fatigue. Psychotherapeut. 2011;56:216–23.CrossRefGoogle Scholar
  6. 6.
    National Comprehensive Cancer Network (NCCN). Cancer-related fatigue. NCCN clinical practice guidelines in oncology. Version 1. 2014. www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 25 September 2014.
  7. 7.
    Bruera E, Yennurajalingham S, Palmer JL, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: A randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31:2421–7.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Fife K, Spathis A, Dutton SJ, et al. A multicenter, randomized, double-blinded, placebo-controlled trial of modafinil for lung cancer-related fatigue: dose response and patient satisfaction data. J Clin Oncol. 2013;31(Suppl):9503.Google Scholar
  9. 9.
    Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011;41:761–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Yennurajalingam S, Palmer JL, Chacko R, Bruera E. Factors associated with response to methylphenidate in advanced cancer patients. Oncologist. 2011;16:246–53.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial. J Clin Oncol. 2010;28:3673–9.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Stone PC. Methylphenidate in the management of cancer-related fatigue. J Clin Oncol. 2013;31:2372–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann Pharmacother. 2009;43:721–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Jean-Pierre P, Morrow GR, Roscoe JA, et al. A Phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer. 2010;15:3513–20.CrossRefGoogle Scholar
  15. 15.
    Spathis A, Fife K, Blackhall F, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32:1882–8.PubMedCrossRefGoogle Scholar
  16. 16.
    European Medicines Agency (EMA). Assessment report for modafinil containing medicinal products. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Modafinil_31/WC500105597.pdf. Accessed 25 September 2014.
  17. 17.
    Minton O, Stone P, Richardson A, Sharpe M, Hotopf M. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev. 2010;(7):CD006704.Google Scholar
  18. 18.
    Dimeo F, Schmittel A, Fietz T, et al. Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Ann Oncol. 2004;15:1237–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys. 2001;51:691–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28:4996–5010.PubMedCrossRefGoogle Scholar
  21. 21.
    Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet.009;373:1532–42.Google Scholar
  22. 22.
    Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15:259–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004;49:139–44.PubMedGoogle Scholar
  24. 24.
    Shih A, Jackson KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother. 2007;21:69–76.PubMedCrossRefGoogle Scholar
  25. 25.
    Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31:3076–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69:751–4.PubMedGoogle Scholar
  27. 27.
    Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients - an EAPC approach. Palliat Med. 2008;22:13–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Kamath J, Yarbrough GG, Prange Jr AJ, Winokur A. The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther. 2009;121:20–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kamath J, Feinn R, Winokur A. Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. Support Care Cancer. 2012;20:1745–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin. 2008;29:1109–18.PubMedCrossRefGoogle Scholar
  31. 31.
    Rasheed N, Tyagi E, Ahmad A, Siripurapu KB, Lahiri S, Shukla R, Palit G. Involvement of monoamines and proinflammatory cytokines in mediating the anti-stress effects of Panax quinquefolium. J Ethnopharmacol. 2008;117:257–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets. CNS Neurosci Ther. 2011;17:761–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Lee NH, Son CG. Systematic review of randomized controlled trials evaluating the efficacy and safety of ginseng. J Acupunct Meridian Stud. 2011;4:85–97.PubMedCrossRefGoogle Scholar
  34. 34.
    Finnegan-John J, Molassiotis A, Richardson A, Ream E. A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. Integr Cancer Ther. 2013;12:276–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, Double-Blind Trial, N07C2. J Natl Cancer Inst. 2013;105:1230–8.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    World Health Organization (WHO). WHO monographs on medicinal plants commonly use in the newly independent states. Geneva: WHO Press; 2010.Google Scholar
  37. 37.
    Kitts DD, Hu C. Efficacy and safety of ginseng. Public Health Nutr. 2000;34:473–85.Google Scholar
  38. 38.
    Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002;25:323–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Campos MP, Riechelmann R, Martins LC, Hassan BJ, Casa FB, Del Giglio A. Effect of guarana (Paullinia cupana) on fatigue in breast cancer patients undergoing systemic chemotherapy. J Clin Oncol. 2010;28:9007.Google Scholar
  40. 40.
    da Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. J Altern Complement Med. 2009;15:431–3.Google Scholar
  41. 41.
    Haensel R, Pertz H. Alkaloide. In: Hänsel R, Sticher O, editors. Pharmakognosie phytopharmazie. Heidelberg: Springer Medizin; 2007:1455–6.CrossRefGoogle Scholar
  42. 42.
    Chen HW, Lin IH, Chen YJ, et al. A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. Clin Invest Med. 2012;35:E1–11.PubMedGoogle Scholar
  43. 43.
    Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75:105–12.PubMedCrossRefGoogle Scholar
  44. 44.
    Barton DL, Atherton PJ, Bauer BA, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. 2011;9:24–31.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Aslanyan G, Amroyan E, Gabrielyan E, Nylander M, Wikman G, Panossian A. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions. Phytomedicine. 2010;17:494–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2015

Authors and Affiliations

  • Joachim Weis
    • 1
  • Markus Horneber
    • 2
  1. 1.Department of Psycho-OncologyTumor Biology CentreFreiburgGermany
  2. 2.Department of Oncology/Hematology Paracelsus Medical UniversityKlinikum NuernbergNuernbergGermany

Personalised recommendations